Immunity to fungal infections

Nature Reviews Immunology

Volumn 4, Issue 1, 2004, Pages 11-23

  Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MYCOSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRULENCE; ANIMAL; DENDRITIC CELL; FUNGUS; HUMAN; INNATE IMMUNITY; PATHOGENICITY; SIGNAL TRANSDUCTION;

CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; TOLL LIKE RECEPTOR;

ANIMALS; DENDRITIC CELLS; FUNGI; HUMANS; IMMUNITY, NATURAL; MEMBRANE GLYCOPROTEINS; MYCOSES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 1542674589     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1255     Document Type: Review

References (131)

1. Romani, L. In Overview of the fungal pathogens (eds Kaufmann, S. H. E., Sher, A. & Ahmed, R) 25-37 (ASM Press, Washington D. C., 2001).
2. Clark, T. A. & Hajjeh, R. A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15, 569-574 (2002).
3. Fleming, R. V., Walsh, T. J. & Anaissie, E. J. Emerging and less common fungal pathogens. Infect. Dis. Clin. North. Am. 16, 915-933 (2002).
4. Hage, C. A., Goldman, M. & Wheat, L. J. Mucosal and invasive fungal infections in HIV/AIDS. Eur. J. Med. Res. 7, 236-241 (2002).
5. Wang, H. et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N. Engl. J. Med. 349, 507-508 (2003).
6. Dixon, D. M. Coccidioides immitis as a select agent of bioterrorism. J. Appl. Microbiol. 91, 602-605 (2001).
7. Odds, F. C., Brown, A. J. & Gow, N. A. Antifungal agents: mechanisms of action. Trends Microbiol. 11, 272-279 (2003).
8. Marr, K. A., Patterson, T. & Denning, D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North. Am. 16, 875-894, vi (2002).
9. Fidel, P. L., Jr. & Sobel, J. D. The role of cell-mediated immunity in candidiasis. Trends Microbiol. 2, 202-206 (1994).
10. H2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3, 237-240 (1995).
11. Romani, L. & Kaufmann, S. H. Immunity to fungi. Res. Immunol. 149, 281-493 (1998).
12. H2 cells and beyond. Curr. Opin. Microbiol. 2, 363-367 (1999).
13. H2 cytokine balance. Int. Rev. Immunol. 21, 423-438 (2002).
14. Huffnagle, G. B. & Deepe, G. S. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr. Opin. Microbiol. 6, 344-350 (2003).
15. Medzhitov, R. & Janeway, C. A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997).
16. Romani, L. In Fungal pathogenesis Principles and clinical applications (eds Calderone, R. A. & Cihlar, L. R.) 401-432 (Marcel Dekker, Inc., New York, 2002).
17. Valore, E. V., Park, C. H., Igreti, S. L. & Ganz, T. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 187, 561-568 (2002).
18. Garlanda, C. et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420, 182-186 (2002).
19. McCormack, F. X. et al. Macrophage-independent fungicidal action of the pulmonary collectins. J. Biol. Chem. 278, 36250-36256 (2003). References 18 and 19 show the essential and unique role played by pulmonary collectins in host defence against airborne fungi.
20. Akira, S. Mammalian Toll-like receptors. Curr. Opin. Immunol, 15, 5-11 (2003).
21. Hoffmann, J. A. & Reichhart, J. M. Drosophila innate immunity: an evolutionary perspective. Naure Immunol. 3, 121-126 (2002).
22. O'Neill, L. A. Fitzgerald, K. A. & Bowie, A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 24, 286-290 (2003).
23. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301, 640-643 (2003).
24. Mambula, S. S., Sau, K., Henneke, P., Golenbock, D. T. & Levitz, S. M. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J. Biol. Chem. 277, 39320-39326 (2002).
25. Netea, M. G. et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185, 1483-1489 (2002).
26. Gantner, B. N., Simmons, R. M., Canavera, S. J., Akira, S. & Underhill, D. M. Collaborative induction of inflammatory responses by Dectin-1 and Toll-like receptor 2. J. Exp. Med. 197, 1107-1117 (2003).
27. Brown, G. D. et al. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 197, 1119-1124 (2003).
28. Jouault, T. et al. Candida albicans phospholipomannan is sensed through toll-like receptors. J. Infect. Dis. 188, 165-172 (2003).
29. Lebron, F., Vassallo, R., Puri, V. & Limper, A. H. Pneumocystis carinii cell wall β-glucans initiate macrophage inflammatory responses through NF-κB activation. J. Biol. Chem. 278, 25001-25008 (2003).
30. Wang, J. E. et al. Involvement of CD14 and Toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect. Immun. 69, 2402-2406 (2001).
31. Netea, M. G. et al. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J. Infect. Dis. 188, 320-326 (2003). This paper shows that avoiding Toll-like receptor (TLR) recognition could be an evasion strategy of virulent fungi.
32. Tada, H. et al. Saccharomyces carevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor α by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 46, 503-512 (2002).
33. Shoham, S., Huang, C., Chen, J. -M., Golenbock, D. T. & Levitz, S. M. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166, 4620-4626 (2001).
34. Beilocchio, S. et al. The contribution of the Toll-like receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. (in the press).
35. Marr, K. A. et al. Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect. Immun. 71, 5280-5286 (2003).
36. Tauszig-Delamasure, S., Bilak, H., Capovilla, M., Hoffmann, J. A. & Imler, J. L. Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections. Nature Immunol. 3, 91-97 (2002).
37. Mansour, M. K. & Levitz, S. M. Interactions of fungi with phagocytes. Curr. Opin. Microbiol. 5, 359-365 (2002).
38. Hamilton, A. J. & Holdon, M. D. Antioxidant systems in the pathogenic fungi of man and their role in virulence. Med. Mycol. 37, 375-389 (1999).
39. Heyworth, P. G., Cross, A. R. & Curnutten J. T. Chronic granulomatous disease. Curr Opin. Immunol. 15, 578-584 (2003).
40. A controlled trial of interferon γ to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N. Engl. J. Med. 324, 509-516 (1991).
41. Dinauer, M. C., Gifford, M. A., Pech, N., Li, L. L. & Emshwiller, P. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 91, 3738-3745 (2001).
42. Bodey, G. P., Buckley, M., Sathe, Y. S. & Freireich, E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64, 328-340 (1966).
43. Walsh, T. J., Hiemenz, J. & Pizzo, P. A. Evolving risk factors for invasive fungal infections-all neutropenic patients are not the same. Clin. Infect. Dis. 18, 793-798 (1994).
44. Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M. & Zanovello, P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24, 302-306 (2003).
45. H1 immunity in mice with candidiasis. J. Immunol. 169, 3180-3190 (2002).
46. Vazquez-Torres, A. & Balish, E. Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. 61, 170-192 (1997).
47. Brandhorst, T. T., Wuthrich, M., Warner, T. & Klein, B. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J. Exp. Med. 189, 1207-1216 (1999).
48. Kugler, S., Schurtz Sebghati, T., Groppe Eissenberg, L. & Goldman, W. E. Phenotypic variation and Intracellular parasitism by Histoplasma capsulatum. Proc. Natl. Acad. Sci. USA 97, 8794-8798 (2000).
49. Tucker, S. C. & Casadevall, A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99, 3165-3170 (2002).
50. Woods, J. P. Knocking on the right door and making a comfortable home: Histoplasma capsulatum intracellular pathogenesis. Curr. Opin. Microbiol. 6, 327-331 (2003).
51. Ibata-Ombetta, S., Idziorek, T., Trinel, P. A., Poulain, D. & Jouault, T. Candida albicans phospholipomannan promotes survival of phagocytosed yeasts through modulation of bad phosphorylation and macrophage apoptosis. J. Biol. Chem. 278, 13086-13093 (2003).
52. Kozel, T. R. Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev. 9, 34-46 (1996).
53. Casadevall, A., Feldmesser, M. & Pirofski, L. -A. Induced humoral immunity and vaccination against major human fungal pathogens. Curr. Opin. Microbiol. 5, 386-391 (2002).
54. Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S. & Carroll, M. C. Complement is essential for protection by an IgM and IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167, 1550-1557.
55. Syme, R. M., Bruno, T. F., Kozel, T. R. & Mody, C. H. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67, 4620-4627 (1999).
56. MacGill, T. C., MacGill, R. S., Casadevall, A. & Kozel, T. R. Biological carrelates of capsular (quelling) reactions of Cryptococcus neoformans. J. Immunol. 164, 4835-4842 (2000).
57. Taborda, C. P. & Casadevall, A. CR3 (CD11/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16, 791-802 (2002). This paper shows that antibodies promote phagocytosis through receptors of innate immunity by altering the capsule of Cryptccoccus neoformans.
58. Bromuro, C. et al. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470 (2002).
59. Sato, M., Sano, H., Iwaki, D., Kudo, K. & Konishi, M. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-κB activation and TNF-α secretion are downregulated by lung collectin surfactant protein A. J. Immunol. 171, 417-425 (2003).
60. Vecchiarelli, A., Pietrella, D., Bistoni, F., Kozel, T. R. & Casadevall, A. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rβ2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunol. 106, 267-272 (2002).
61. Ezekowitz, R. A. et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 351, 155-158 (1991).
62. Long, K. H., Gomez, F. J., Morris, R. E. & Newman, S. L. Identification of heat shock protein 60 as the ligand on Histoplasma capsulatum that mediates binding to CD18 receptors on human macrophages. J. Immunol. 170, 487-494 (2003).
63. Gildea, L. A., Morris, R. E. & Newman, S. L. Histoplasma capsulatum yeasts are phagocytosed via very late antigen-5, killed, and processed for antigen presentation by human dendritic cells. J. Immunol. 166, 1049-1056 (2001).
64. Herring, A. C. & Huffnagle, G. B. In Immunology of Infectious Diseases (eds Kaufmann, S. H. E., Sher, A. & Ahmed, R.) 127-137 (ASM Press, Washington D. C., 2001).
65. Cheng, V. C. et al. Immunorestitution disease involving the innate and adaptive response. Clin. Infect. Dis. 30, 882-892 (2000).
66. Warris, A., Bjorneklett, A. & Gaustad, P. Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. 344, 1099-1100 (2001).
67. Wood, K. L. et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am. J. Respir. Crit. Care Med. 167, 1279-1282 (2003).
68. Romani, L., Bistoni, F. & Puccetti, P. Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol. 10, 508-514 (2002).
69. Romani, L., Puccetti, P. & Bistoni, F. Interleukin-12 in infectious diseases. Clin. Microbiol. Rev. 10, 611-636 (1997).
70. Marth, T. & Kelsall, B. L. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185, 1987-1995 (1997).
71. Roilides, E., Lamaignere, C. G. & Farmaki, E. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int. J. Infect. Dis. 6, 154-163 (2002).
72. Marodi, L. Deficient interferon-γ receptor-mediated signaling in neonatal macrophages. Acta Paediatr. Suppl. 91, 117-119 (2002).
73. H immunity and vaccination. Curr. Mol. Med. 2, 507-524 (2002).
74. H-cell responses.
75. Huang, Q. et al. The plasticity of dendritic cell responses to pathogens and their components. Science 294, 870-875 (2001).
76. Syme, R. M., Spurrell, J. C., Amankwah, E. K., Green, F. H. & Mody, C. H. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcγ receptor II for presentation to T lymphocytes. Infect. Immun. 70, 5972-5981 (2002).
77. Mansour, M. K., Schlesinger, L. S. & Levitz, S. M. Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J. Immunol. 168, 2872-2879 (2002).
78. Babula, O., Lazdane, G., Kroica, J., Ledger, W. J. & Witkin, S. S. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin. Infect. Dis. 37, 733-737 (2003).
79. Crosdale, D. J., Poulton, K. V., Ollier, W. E., Thomson, W. & Denning, D. W. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J. Infect. DiS. 184, 653-656 (2001).
80. Montagnoli, C. et al. A role for antibodies in the generation of memory antifungal immunity. Eur. J. Immunol. 33, 1193-1204 (2003).
81. Brown, A. J. In Candida and candidiasis. (ed. Calderone, A. R.) 87-106 (ASM Press, Washington D. C., 2002).
82. Romani, L., Bistoni, F. & Puccetti, P. Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts. Curr. Opin. Microbiol. 6, 338-343 (2003).
83. Murphy, J. W. Immunity to fungi. Curr. Opin. Immunol. 2, 360-367 (1989).
84. Romani, L. The T cell response against fungal infections. Curr. Opin. Immunol. 9, 484-490 (1997).
85. Netea, M. G., Stuyt, R. J., Kim, S. H., Van der Meer, J. W., Kullberg, B. J. & Dinarello, C. A. The role of endogenous interleukin (IL)-18, IL-12, IL-1β, and tumor necrosis factor-α in the production of interferon-ω induced by Candida albicans in human whole-blood cultures. J. Infect. Dis. 185, 963-970 (2002).
86. Hebart, H. et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 100, 4521-4528 (2002).
87. Levitz, S. M., Mathews, H. L. & Murphy, J. W. Direct anti-microbial activity of T cells. Immunol. Today 16, 387-391 (1995).
88. Ma, L. L. et al. CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J. Immunol. 169, 5787-5795 (2002).
89. Huffnagle, G. B., Yates, J. L. & Lipscomb, M. F. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4- and CD8-T cells. J. Exp. Med. 173, 793-800 (1991).
90. Deepe, G. S., Jr. & Gibbons, R. S. Functional properties of the T cell receptor repertoire in responding to the protective domain of heat-shock protein 60 from Histoplasma capsulatum. J. Infect. Dis. 188, 815-822 (2002).
91. Wuthrich, M., Filutowicz, H. I., Warner, T. & Klein, B. S. Requisite elements in vaccine immunity to Blastomyces dermatitidis: plasticity uncovers vaccine potential in immune-deficient hosts. J. Immunol. 169, 6969-6976 (2002).
92. + T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197, 1405-1416 (2003). References 91 and 92 describe the cellular and molecular requirements for vaccine-induced immunity to fungi and the feasibility of a fungal vaccine for immunodeficient recipients.
93. Marr, K. A., Carter, R. A., Boeckh, M., Martin, P. & Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
94. Magee, D. M. & Cox, R. A. in Fungal pathogenesis. Principles and clinical applications (eds Calderone, R. A. & Cihlar, L. R.) 279-292 (Marcel Dekker, Inc., New York, 2002).
95. Calich, V. L., Vaz, C. A. & Burger, E. Immunity to Paracoccidioides brasiliensis infection. Res. Immunol. 149, 407-417 (1998).
96. Clemons, K. & Stevens, D. A. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Seminar. Respir. Infect 16, 60-66 (2001).
97. H2 cytokine imbalance in a family with hyper-IgE syndrome. Neth J. Med. 60, 349-353 (2002).
98. Savolainen, J., Koivikko, A., Kalimo, K., Nieminen, E. & Viander, M. IgE, IgA and IgG antibodies and delayed skin response towards Candida albicans antigens in atopics with and without saprophytic growth. Clin. Exp. Allergy 20, 549-554 (1990).
99. Faergemann, J. Atopic dermatitis and fungi. Clin. Microbiol. Rev. 15, 545-563 (2002).
100. Choi, E. H. et al. Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J. Infect. Dis. 187, 1153-1156 (2003).
101. Lilic, D. New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr. Opin. Infect. Dis. 15, 143-147 (2002).
102. Roilides, E., Sein, T., Schaufele, R., Chanock, S. J. & Walsh, T. J. Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis. J. Infect. Dis. 178, 589-592 (1998).
103. Peracoli, M. T. et al. Production of pro- and anti-inflammatory cytokines by monocytes from patients with paracoccioioidomycoses. Microbes Infect. 5, 413-418 (2003).
104. Roilides, E., Sein, T., Roden, M., Schaufele, R. L. & Walsh, T. J. Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J. Infect. Dis. 183, 518-520 (2001).
105. + T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur. J. Immunol. 32, 1282-1291 (2002).
106. Ashman, R. B. & Papadimitriou, J. M. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol. Rev. 59, 646-672 (1995).
107. Liston, A., Lesage, S., Wilson, J., Peltonen, L. & Goodnow, C. C. Aire regulates negative selection of organ-specific T cells. Nature Immunol. 4, 350-435 (2003).
108. Fidel, P. L., Jr. The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models. Int. Rev. Immunol. 21, 515-548 (2002).
109. Stevens, D. A. et al. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 1, 305-315 (2000).
110. Sau, K. et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a toll-like receptor and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568 (2003). The first evidence that antifungal agents use TLRs for efficacy and toxicity.
111. Deepe, G. S., Jr. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10, 585-596 (1997).
112. Levitz, S. M., Nong, S., Mansour, M. K., Huang, C. & Specht, C. A. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl Acad. Sci. USA 98, 10422-10427 (2001).
113. Bauman, S. K., Nichols, K. L. & Murphy, J. W. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J. Immunol. 165, 158-167 (2000).
114. H responses to the fungus. J. Immunol. 168, 1362-1371 (2002).
115. Ferreira, K. S., Lopes, J. D. & Almeida, S. R. Regulation of T helper cell differentiation in vivo by GP43 from Paracoccidioides brasiliensis provided by different antigen-presenting cells. Scand. J. Immunol. 58, 290-297 (2003)
116. Bozza, S. et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102, 3807-3814 (2003).
117. Graziutti, M. et al. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 27, 647-652 (2001).
118. Richards, J. O., Ampel, N. M. & Lake, D. F. Reversal of coccidioidal anergy in vitro by dendritic cells from patients with disseminated coccidioidomycosis. J. Immunol. 169, 2020-2025 (2002).
119. Magee, P. T., Gale, C., Berman, J. & Davis, D. Molecular genetic and genomic approaches to the study of medically important fungi. Infect. Immun. 71, 2299-2309 (2003).
120. Lorenz, M. C. & Fink, G. R. The glyoxylate cycle is required for fungal virulence. Nature 412, 83-86 (2001). An example of the application of genomics to the study of fungal pathogenesis and virulence.
121. De Backer, M. D., Van Dijck, P. & Luyten, W. H. Functional genomics approaches for the identification and validation of antifungal drug targets. Am. J. Pharmacogenomics 2, 113-127 (2002).
122. Hogan, L., Klein, B. & Levitz, S. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9, 469-488 (1996).
123. Latgé, J. P. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9, 382-389 (2001).
124. Kirkland, T. N. & Cole, G. T. In Fungal pathogenesis. Principles and Clinical Applications (eds Calderone, R. A. & Cihlar, L. R.) 365-399 (Marcel Dekker, Inc., New York, 2002).
125. Rooney, P. J. & Klein, B. S. Linking fungal morphogenesis with virulenCe. Cell Microbiol. 4, 127-137 (2002).
126. Gow, N. A., Brown, A. J. & Odds, F. C. Fungal morphogenesis and host invasion. Curr. Opin. Microbiol. 5, 366-371 (2002).
127. De Bernardis, F. et al. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65, 3399-3405 (1997).
128. Matthews, R. & Burnie, J. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr. Opin. Investig. Drugs 2, 472-476 (2001).
129. Cutler, J. E., Granger, B. L. & Han, Y. Candida and Candidiasis (ed. Calderone, R. A.) 243-256 (ASM Press, Washington D. C., 2002).
130. Cassone, A., Conti, S., De Bernardis, F. & Polonelli, L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol. Today 18, 164-169 (1997).
131. Magliani, W. et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nature Biotechnol. 15, 155-158 (1997).